Page last updated: 2024-12-06

eproxindine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Eproxindine is a synthetic anticonvulsant drug that was developed in the 1970s. It acts as a GABAergic agonist, meaning it enhances the effects of the neurotransmitter GABA in the brain. This action helps to suppress excessive neuronal activity that can lead to seizures. Eproxindine was initially studied for its potential to treat epilepsy, but it was ultimately found to be ineffective in clinical trials. Despite this, it remains of interest to researchers as a potential lead compound for the development of new anticonvulsants. The drug's mechanism of action and its effects on GABAergic neurotransmission continue to be investigated, potentially leading to new insights into the treatment of epilepsy and other neurological disorders.'

eproxindine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID54965
CHEMBL ID254194
SCHEMBL ID1813780
MeSH IDM0129009

Synonyms (26)

Synonym
kc 3791
n-(3-(diethylamino)-2-hydroxypropyl)-3-methoxy-1-phenyl-1h-indole-2-carboxamide
einecs 288-591-3
85793-29-9
eproxindine
CHEMBL254194
n-[3-(diethylamino)-2-hydroxypropyl]-3-methoxy-1-phenylindole-2-carboxamide
(+-)-n-(3-(diethylamino)-2-hydroxypropyl)-3-methoxy-1-phenylindole-2-carboxamide
eproxindina
eproxindine [inn]
83200-08-2
eproxindina [spanish]
e229k2he7f ,
eproxindinum
unii-e229k2he7f
eproxindinum [latin]
eproxindine [who-dd]
eproxindine [mart.]
(+/-)-n-(3-(diethylamino)-2-hydroxypropyl)-3-methoxy-1-phenylindole-2-carboxamide
JZQYAVBXJCQSOK-UHFFFAOYSA-N
2-[3-(n,n-diethylamino)-2-hydroxypropylaminocarbonyl]-3-methoxy-1-phenylindole
SCHEMBL1813780
n-[3-(diethylamino)-2-hydroxypropyl]-3-methoxy-1-phenyl-1h-indole-2-carboxamide
Q27276763
n-(3-(diethylamino)-2-hydroxypropyl)-3-methoxy-1-phenylindole-2-carboxamide
DTXSID50868697

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (85.71)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (14.29%)5.53%
Reviews0 (0.00%)6.00%
Case Studies2 (28.57%)4.05%
Observational0 (0.00%)0.25%
Other4 (57.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]